Tradestie Institutional Equity Comparison Engine
LLY vs NVO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LLY Overall Edge
LLY Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eli Lilly & Co. (LLY) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NVO counters with relative strength in Valuation. Fundamentally, LLY trades at 28.5x Forward P/E with 51.2% operating margin (+38.6% YoY revenue) versus NVO at 12.2x Forward P/E and 50.8% operating margin (+5.6% YoY). In options structure, LLY sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro) against NVO sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
NVO
LLY 28.5x vs NVO 12.2x Fwd P/E
Growth & Margin Winner
LLY
Op Margin 51.2% vs 50.8% ยท YoY +38.6% vs +5.6%
Momentum & Technical Winner
LLY
1Y +41.1% vs -15.2% ยท 52W Pos 95% vs 23%
Options & Structure Winner
LLY
BREAKOUT (12th %ile IV) vs CONSOLIDATION (25th %ile IV)
LLY
NYSE
Eli Lilly & Co.
Pharmaceutical Preparations
$1,443.11
-0.03% 1D
Market Cap
$1.27T
1M Return
+14.8%
1Y Return
+41.08%
Forward P/E
28.5x
Unified AI Score
36.5 / 100
SELL
Tech 20.0
Fund 45.0
Flow 64.0
Mom 40.0
NVO
NYSE
Novo-Nordisk A/S
Pharmaceutical Preparations
$41.71
+0.19% 1D
Market Cap
$180.7B
1M Return
+7.42%
1Y Return
-15.15%
Forward P/E
12.2x
Unified AI Score
41.8 / 100
SELL
Tech 56.0
Fund 55.0
Flow 58.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LLY +41.08%
NVO -15.15%
Spread: +56.23 pp (LLY Lead)
Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | LLY Revenue | NVO Revenue | LLY Op. Margin | NVO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| Q3 '25 | $70.4B | $46.3B | 47.6% | 31.6% | LLY |
| Q4 '25 | $77.2B | $48.8B | 46.6% | 40.1% | LLY |
| Q1 '26 | $79.2B | $59.7B | 49.4% | 61.6% | NVO |
| Q2 '26 | $91.9B | $48.4B | 54.2% | 34.5% | LLY |
| Q3 '26 | $97.6B | $48.9B | 53.7% | 29.1% | LLY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LLY | NVO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.27T | $180.7B | Larger Scale | LLY |
| Trailing P/E Ratio Valuation | 46.3x | 10.3x | Lower Multiple | NVO |
| Forward P/E Ratio Valuation | 28.5x | 12.2x | Lower Multiple | NVO |
| Revenue Growth (YoY) Growth | +38.6% | +5.6% | Higher Growth | LLY |
| Operating Margin (TTM) Profitability | 51.2% | 50.8% | Higher Margin | LLY |
| Net Profit Margin Profitability | 31.9% | 33.9% | Higher Margin | NVO |
| Return on Equity (ROE) Capital Efficiency | 86.0% | 58.4% | Higher ROE | LLY |
| 52-Week Range Position Momentum | 95% ($851โ$1,475) | 23% ($35โ$64) | Stronger Trend | LLY |
| Beta / 30D Volatility Risk Regime | 0.30ฮฒ ยท 37% Vol | 0.50ฮฒ ยท 32% Vol | Lower Realized Risk | NVO |
| Unified Institutional Score Composite Signal | 36.5 / 100 (SELL) | 41.8 / 100 (SELL) | Higher Composite | NVO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LLY vs NVO Buy Guide
LLY
BREAKOUT
92d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
NVO
CONSOLIDATION
94d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LLY nor NVO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.